- Query in any language with multilingual search
- Access EUR-Lex and EU Commission case law
- See relevant paragraphs highlighted instantly
Similar Documents
Explore similar documents to your case.We Found Similar Cases for You
Case T-511/14: Order of the General Court of 25 October 2017 — Novartis Europharm v Commission (Medicinal products for human use — Marketing authorisation for the medicinal product Zoledronic acid Teva Generics — Zoledronic acid — Period of protection of the medicinal product Aclasta containing the active substance zoledronic acid — Withdrawal of the contested measure — No need to adjudicate)
ECLI:EU:UNKNOWN:62014TB0511
62014TB0511
With us you find everything. Try it now!
I imagine what I want to write in my case, I write it in the search engine and I get exactly what I wanted. Thank you!
Valentina R., lawyer
8.1.2018
Official Journal of the European Union
C 5/42
(Case T-511/14) (<span class="super note-tag">1</span>)
((Medicinal products for human use - Marketing authorisation for the medicinal product Zoledronic acid Teva Generics - Zoledronic acid - Period of protection of the medicinal product Aclasta containing the active substance zoledronic acid - Withdrawal of the contested measure - No need to adjudicate))
(2018/C 005/56)
Language of the case: English
Parties
Applicant: Novartis Europharm Ltd (Camberley, United Kingdom) (represented by: C. Schoonderbeek, lawyer)
Defendant: European Commission (represented by: A. Sipos and M. Wilderspin, Agents)
Re:
Action brought under Article 263 TFEU seeking annulment of Commission Implementing Decision C(2014) 2155 final of 27 March 2014 granting a marketing authorisation to Teva Generics BV for the medicinal product for human use Zoledronic acid Teva Generics — Zoledronic Acid under Article 3 of Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency (OJ 2004 L 136, p. 1).
Operative part of the order
1.There is no longer any need to adjudicate on the action.
2.There is no longer any need to adjudicate on Teva BV’s application for leave to intervene.
3.Each party shall bear its own costs.
(<span class="super">1</span>) OJ C 388, 3.11.2014.